CN109415770A - 乳腺癌标志物及应用 - Google Patents

乳腺癌标志物及应用 Download PDF

Info

Publication number
CN109415770A
CN109415770A CN201880002722.7A CN201880002722A CN109415770A CN 109415770 A CN109415770 A CN 109415770A CN 201880002722 A CN201880002722 A CN 201880002722A CN 109415770 A CN109415770 A CN 109415770A
Authority
CN
China
Prior art keywords
circtada2a
circrna
breast cancer
expression
circnol10
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880002722.7A
Other languages
English (en)
Other versions
CN109415770B (zh
Inventor
陈敏
徐建震
于浩洋
张国君
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Genebiohealth Co ltd
Original Assignee
Shenzhen Genebiohealth Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Genebiohealth Co ltd filed Critical Shenzhen Genebiohealth Co ltd
Priority to CN202211045951.1A priority Critical patent/CN115992201A/zh
Publication of CN109415770A publication Critical patent/CN109415770A/zh
Application granted granted Critical
Publication of CN109415770B publication Critical patent/CN109415770B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本申请涉及作为乳腺癌标志物的circRNA及其用途，所述circRNA选自circTADA2A‑E6、circTADA2A‑E5/E6、circNOL10、circNSUN2、circCSRNP2、circFAM125B、circCDC27和circABCC1。本发明还涉及用于乳腺癌诊断、预后和治疗的试剂盒、微阵列、药物以及相关的方法和用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880002722.7A 2017-05-16 2018-05-10 乳腺癌标志物及应用 Active CN109415770B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211045951.1A CN115992201A (zh) 2017-05-16 2018-05-10 乳腺癌标志物及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017103417975 2017-05-16
CN201710341797.5A CN108220433B (zh) 2017-05-16 2017-05-16 乳腺癌标志物及其应用
PCT/CN2018/086238 WO2018210173A1 (zh) 2017-05-16 2018-05-10 乳腺癌标志物及应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211045951.1A Division CN115992201A (zh) 2017-05-16 2018-05-10 乳腺癌标志物及其应用

Publications (2)

Publication Number Publication Date
CN109415770A true CN109415770A (zh) 2019-03-01
CN109415770B CN109415770B (zh) 2022-08-05

Family

ID=62658111

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201710341797.5A Active CN108220433B (zh) 2017-05-16 2017-05-16 乳腺癌标志物及其应用
CN202211045951.1A Pending CN115992201A (zh) 2017-05-16 2018-05-10 乳腺癌标志物及其应用
CN201880002722.7A Active CN109415770B (zh) 2017-05-16 2018-05-10 乳腺癌标志物及应用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201710341797.5A Active CN108220433B (zh) 2017-05-16 2017-05-16 乳腺癌标志物及其应用
CN202211045951.1A Pending CN115992201A (zh) 2017-05-16 2018-05-10 乳腺癌标志物及其应用

Country Status (2)

Country Link
CN (3) CN108220433B (zh)
WO (1) WO2018210173A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110004228A (zh) * 2019-04-03 2019-07-12 清华大学深圳研究生院 一种与乳腺癌分子分型相关的诊断标志物及其用途
CN115074442A (zh) * 2022-06-29 2022-09-20 柳州市人民医院 两种快速鉴别早期鼻咽癌的环状rna标志物的应用及诊断试剂盒

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108220433B (zh) * 2017-05-16 2021-04-02 深圳市晋百慧生物有限公司 乳腺癌标志物及其应用
CN108796086B (zh) * 2018-07-04 2021-07-30 聊城市人民医院 一种环状RNAcircBCBM1及其非诊断性荧光定量检测方法
CN109022583A (zh) * 2018-08-24 2018-12-18 中国医学科学院肿瘤医院 hsa_circ_0021977在制备诊断乳腺癌产品上的应用
CN109295059B (zh) * 2018-09-13 2022-06-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种共价环状闭合单链rna在三阴乳腺癌试剂盒中的应用
CN109280705A (zh) * 2018-12-11 2019-01-29 宁夏医科大学总医院 一种环状RNA hsa-circ-0044506及其特异性扩增引物和应用
CN109402126A (zh) * 2018-12-11 2019-03-01 宁夏医科大学总医院 一种环状RNA hsa-circ-0044513及其特异性扩增引物和应用
CN109402120A (zh) * 2018-12-11 2019-03-01 宁夏医科大学总医院 一种环状RNA hsa-circ-0054020及其特异性扩增引物和应用
CN109371030A (zh) * 2018-12-11 2019-02-22 宁夏医科大学总医院 一种环状RNA hsa-circ-0131864及其特异性扩增引物和应用
CN109371027A (zh) * 2018-12-11 2019-02-22 宁夏医科大学总医院 一种环状RNA hsa-circ-0002938及其特异性扩增引物和应用
CN109402122A (zh) * 2018-12-11 2019-03-01 宁夏医科大学总医院 一种环状RNA hsa-circ-0044551及其特异性扩增引物和应用
CN110093419B (zh) * 2019-04-26 2023-10-27 北京大学深圳医院 环状rna的应用、试剂盒和药物组合物及其应用
CN110859861A (zh) * 2019-12-04 2020-03-06 武汉工程大学 植物病原微生物杀灭癌细胞或艾滋病病毒的用途
CN111269985B (zh) * 2020-03-20 2020-10-30 安阳市肿瘤医院 hsa_circRNA6448-14在食管鳞癌诊断以及预后预测中的应用
IT202000019045A1 (it) * 2020-08-03 2022-02-03 St Fisioterapici Ospitalieri Ifo Metodo per la diagnosi in vitro del rischio di recidiva e/o metastasi nei pazienti con tumore della mammella triplo negativo e relativo kit
CN113913524B (zh) * 2021-11-09 2023-07-18 上海市第十人民医院 乳腺癌循环标志物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108220433B (zh) * 2017-05-16 2021-04-02 深圳市晋百慧生物有限公司 乳腺癌标志物及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108220433B (zh) * 2017-05-16 2021-04-02 深圳市晋百慧生物有限公司 乳腺癌标志物及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LU LINGSHUANG等: "Identification of circular RNAs as a promising new class of diagnostic biomarkers for human breast cancer", 《ONCOTARGET》 *
SU,HUAFANG等: "Profiling and Bioinformatics Analysis Reveal Differential Circular RNA Expression in Radioresistant Esophageal Cancer Cells", 《JOURNAL OF TRANSLATIONAL MEDICINE》 *
XIE HUIJUN等: "Emerging Roles of circRNA_001569 Targeting miR-145 in the Proliferation and Invasion of Colorectal Cancer", 《ONCOTARGET》 *
高鹏骥等: "环状RNA在肝细胞癌中的差异表达研究", 《中国普通外科杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110004228A (zh) * 2019-04-03 2019-07-12 清华大学深圳研究生院 一种与乳腺癌分子分型相关的诊断标志物及其用途
CN115074442A (zh) * 2022-06-29 2022-09-20 柳州市人民医院 两种快速鉴别早期鼻咽癌的环状rna标志物的应用及诊断试剂盒

Also Published As

Publication number Publication date
WO2018210173A1 (zh) 2018-11-22
CN108220433A (zh) 2018-06-29
CN108220433B (zh) 2021-04-02
CN109415770B (zh) 2022-08-05
CN115992201A (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
CN109415770A (zh) 乳腺癌标志物及应用
Cesarini et al. ADAR2/miR-589-3p axis controls glioblastoma cell migration/invasion
Wang et al. Gene networks and microRNAs implicated in aggressive prostate cancer
EP3268494B1 (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
Jung et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy
Hu et al. Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls
Nadal et al. A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma
Bartels et al. MicroRNAs: novel biomarkers for human cancer
Ziebarth et al. Integrative analysis of somatic mutations altering microRNA targeting in cancer genomes
EP2799557B1 (en) MiR-32 antagonists for increasing responsiveness of prostate cancer to apoptosis
US20120283310A1 (en) MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CLL) and Uses Thereof
Zhan et al. MicroRNA-548j functions as a metastasis promoter in human breast cancer by targeting Tensin1
Zhang et al. Serum microRNA‐150 predicts prognosis for early‐stage non‐small cell lung cancer and promotes tumor cell proliferation by targeting tumor suppressor gene SRCIN1
Chen et al. Downregulated pseudogene CTNNAP1 promote tumor growth in human cancer by downregulating its cognate gene CTNNA1 expression
Wimmer et al. A cancer stem cell-like phenotype is associated with miR-10b expression in aggressive squamous cell carcinomas
Yang et al. Long non-coding RNA p10247, high expressed in breast cancer (lncRNA-BCHE), is correlated with metastasis
Ge et al. A BAP1 mutation-specific MicroRNA signature predicts clinical outcomes in clear cell renal cell carcinoma patients with wild-type BAP1
Mueller et al. The evolving concept of ‘melano-miRs’–microRNAs in melanomagenesis.
Tan et al. Overexpression of novel long intergenic non‑coding RNA LINC02454 is associated with a poor prognosis in papillary thyroid cancer
de Bony et al. Comprehensive identification of long noncoding RNAs in colorectal cancer
Lemberger et al. MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis
Zhao Single nucleotide alterations in MicroRNAs and human cancer-A not fully explored field
JP2011520454A (ja) 結腸直腸癌を評価する方法及びかかる方法に使用するための組成物
Xu et al. A 3‐miRNA signature predicts survival of patients with hypopharyngeal squamous cell carcinoma after post‐operative radiotherapy
WO2018209024A1 (en) Methods of identifying mirnas and applications thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant